Canaccord raised the firm’s price target on AtriCure (ATRC) to $66 from $61 and keeps a Buy rating on the shares. The firm said they posted a solid Q4 and management raised the low-end of its adjusted EBITDA expectation by $2M due to a strong YE24.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATRC: